Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?
Open accessAbstract
Background: Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly. Methods: PubMed and Google Scholar were searched for articles about the use of CGM in individuals without diabetes. Relevant articles that included sufficient details were queried to identify what cohorts of individuals were adopting CGM use and to define trends of use. Results: Four clinical user cases were identified: (1) metabolic diseases related to diabetes with a primary dysregulation of the insulin-glucose axis, (2) metabolic diseases without a primary pathophysiologic derangement of the insulin-glucose axis, (3) health and wellness, and (4) elite athletics. Seven trends in the use of CGM systems in people without diabetes were idenfitied which pertained to both FDA-cleared medical grade products as well as anticipated future products, which may be regulated differently based on intended populations and indications for use. Conclusions: Wearing a CGM has been used not only for diabetes, but with a goal of improving glucose patterns to avoid diabetes, improving mental or physical performance, and promoting motivate healthy behavioral changes. We expect that clinicians will become increasingly aware of (1) glycemic patterns from CGM tracings that predict an increased risk of diabetes, (2) specific metabolic glucotypes from CGM tracings that predict an increased risk of diabetes, and (3) new genetic and genomic biomarkers in the future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Continuous use of CGMs in non-insulin users can be burdensome physically and financially and may not provide immediate perceived benefits.
“continuous use of CGMs in non-insulin users can sometimes be burdensome both physically and financially due to the invasiveness and cost of the devices, and may not provide immediate perceived benefits7.”
From Impact of digital health interventions on glycemic control and weight management. (2025) · cites this paper as [7]
Recent developments have made CGM more available to individuals with diet-controlled diabetes or no diabetes, placing CGM center-stage in efforts to prevent diabetes through lifestyle modifications.
“recent developments have made CGM more available to individuals with diet-controlled diabetes or no diabetes, thereby placing CGM center-stage in efforts to prevent diabetes through lifestyle modifications such as healthier food choices and increased physical activity6,7.”
From Impact of digital health interventions on glycemic control and weight management. (2025) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 70 · Cited by 93
- Authors
- Klonoff, D. C., Nguyen, K. T., Xu, N. Y., Gutierrez, A., Espinoza, J. C., & Vidmar, A. P.
- Affiliations
- San Mateo Medical Center (US)
- Diabetes Technology Society (US)
- NDA Partners LLC, Bethesda, MD, USA
- University of Southern California (US)
- Corresponding author
- Klonoff, David C.
- ORCID
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2022-07-20
- Volume
- 17
- Issue
- 6
- Pages
- 1686-1697
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC10658694
- OpenAlex
- W4286210600
- Cited by
- 93
- References
- 70
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 14 · 2023: 12 · 2022: 1
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001855)
- U.S. Food and Drug Administration (P50FD006425)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Physiology › Physical Activity and Health
- Keywords
- continuous glucose monitoring, non-diabetic population, athletic performance, diabetes prevention
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Insulin, Blood Glucose Self-Monitoring, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review